Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tracy Todd Batchelor, M.D.

Co-Author

This page shows the publications co-authored by Tracy Batchelor and David Louis.
Connection Strength

3.294
  1. Case records of the Massachusetts General Hospital. Case 17-2012. A 54-year-old man with visual-field loss and a mass in the brain. N Engl J Med. 2012 May 31; 366(22):2112-20.
    View in: PubMed
    Score: 0.525
  2. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):228-33.
    View in: PubMed
    Score: 0.293
  3. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018 04; 135(4):639-642.
    View in: PubMed
    Score: 0.196
  4. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol. 2018 03; 135(3):481-484.
    View in: PubMed
    Score: 0.194
  5. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol. 2017 01; 133(1):1-3.
    View in: PubMed
    Score: 0.181
  6. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2017 11; 27(6):851-852.
    View in: PubMed
    Score: 0.180
  7. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol. 2013 May 10; 31(14):e233-6.
    View in: PubMed
    Score: 0.139
  8. Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas. Acta Neuropathol. 2011 Apr; 121(4):529-43.
    View in: PubMed
    Score: 0.118
  9. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
    Score: 0.114
  10. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin Neurosurg. 2008; 55:165-71.
    View in: PubMed
    Score: 0.097
  11. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007 Apr 01; 13(7):2038-45.
    View in: PubMed
    Score: 0.092
  12. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
    Score: 0.090
  13. Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):704-10.
    View in: PubMed
    Score: 0.081
  14. Statistical considerations for immunohistochemistry panel development after gene expression profiling of human cancers. J Mol Diagn. 2005 May; 7(2):276-82.
    View in: PubMed
    Score: 0.080
  15. Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study. Neuro Oncol. 2005 Jan; 7(1):97-100.
    View in: PubMed
    Score: 0.079
  16. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003 Apr 01; 63(7):1602-7.
    View in: PubMed
    Score: 0.070
  17. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003 Mar; 9(3):1063-9.
    View in: PubMed
    Score: 0.069
  18. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21.
    View in: PubMed
    Score: 0.054
  19. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol. 2019 05 06; 21(5):596-605.
    View in: PubMed
    Score: 0.053
  20. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol Commun. 2019 04 29; 7(1):66.
    View in: PubMed
    Score: 0.053
  21. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335.
    View in: PubMed
    Score: 0.049
  22. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View in: PubMed
    Score: 0.046
  23. Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. J Clin Neurosci. 2016 Sep; 31:99-105.
    View in: PubMed
    Score: 0.043
  24. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
  25. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014 Dec 24; 2:167.
    View in: PubMed
    Score: 0.039
  26. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309.
    View in: PubMed
    Score: 0.038
  27. American brain tumor association young investigator award 198 circulating tumor cells in patients with glioblastoma. Neurosurgery. 2014 Aug; 61 Suppl 1:226.
    View in: PubMed
    Score: 0.038
  28. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013 Jan; 10(1):14-26.
    View in: PubMed
    Score: 0.034
  29. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
    View in: PubMed
    Score: 0.033
  30. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol. 2012 Jan 20; 30(3):e30-3.
    View in: PubMed
    Score: 0.032
  31. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948.
    View in: PubMed
    Score: 0.030
  32. Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. J Neurooncol. 2009 May; 93(1):115-20.
    View in: PubMed
    Score: 0.027
  33. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol. 2006 Dec; 65(12):1181-8.
    View in: PubMed
    Score: 0.022
  34. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006 Apr 15; 66(8):3987-91.
    View in: PubMed
    Score: 0.021
  35. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8600-5.
    View in: PubMed
    Score: 0.021
  36. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res. 2005 Mar 15; 11(6):2258-64.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.